2021
Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade
Peters GW, Tao W, Wei W, Miccio JA, Jethwa KR, Cecchini M, Johung KL. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. The Oncologist 2021, 26: 660-667. PMID: 33728733, PMCID: PMC8342580, DOI: 10.1002/onco.13759.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials, Phase III as TopicHumansLogistic ModelsMedical OncologyNeoplasmsPublication BiasRandomized Controlled Trials as TopicConceptsGI oncologyPublication biasImpact of RCTsFuture trial designMultivariable logistic regressionSignificant publication biasPast trialsAccrual completionCancer RCTsEvidence-based practiceGastrointestinal cancerClinical managementTrial completionTrial designOncology trialsClinical practicePublication statusRCTsTrial questionModern RCTsLogistic regressionHalf of trialsTrialsPhase IIIGold standard
2017
Olaratumab for the treatment of soft tissue sarcoma.
Deshpande HA, Cecchini M, Ni Choileain S, Jones R. Olaratumab for the treatment of soft tissue sarcoma. Drugs Of Today 2017, 53: 247-255. PMID: 28492292, DOI: 10.1358/dot.2017.53.4.2560077.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAntineoplastic AgentsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicHumansRandomized Controlled Trials as TopicSarcomaConceptsSoft tissue sarcomasPhase II studyTissue sarcomasII studyMetastatic diseaseOverall survivalOngoing phase III studiesRandomized phase II studyPlatelet-derived growth factor receptor alphaProgression-free survivalPhase III studyStandard chemotherapy regimensGrowth factor receptor alphaUnited States FoodMechanism of actionChemotherapy regimensIII studyOngoing trialsSolid malignanciesReceptor alphaPhase IbDrug AdministrationSignificant improvementFDA approvalOlaratumab